<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24411/2587-7836-2019-10055</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-102</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ФАРМАКОКИНЕТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL PHARMACOKINETICS</subject></subj-group></article-categories><title-group><article-title>Результаты двойного слепого, рандомизированного, сравнительного, перекрестного исследования фармакокинетики и фармакодинамики препаратов генно-инженерного инсулина человека</article-title><trans-title-group xml:lang="en"><trans-title>Results of a double-blind, randomized, comparative, cross-sectional study of the pharmacokinetics and pharmacodynamics of genetically engineered human insulin preparations</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Майоров</surname><given-names>Александр Юрьевич</given-names></name><name name-style="western" xml:lang="en"><surname>Mayorov</surname><given-names>Alexander</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авдеева</surname><given-names>Ольга Ильинична</given-names></name><name name-style="western" xml:lang="en"><surname>Avdeeva</surname><given-names>Olga</given-names></name></name-alternatives><email xlink:type="simple">olga.avdeeva@geropharm.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кокшарова</surname><given-names>Екатерина Олеговна</given-names></name><name name-style="western" xml:lang="en"><surname>Koksharova</surname><given-names>Ekaterina</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беликова</surname><given-names>Татьяна Михайловна</given-names></name><name name-style="western" xml:lang="en"><surname>Belikova</surname><given-names>Tatyana</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мишина</surname><given-names>Екатерина Евгеньевна</given-names></name><name name-style="western" xml:lang="en"><surname>Mishina</surname><given-names>Ekaterina</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драй</surname><given-names>Роман Васильевич</given-names></name><name name-style="western" xml:lang="en"><surname>Dray</surname><given-names>Roman</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт диабета ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Diabetes of National Medical Research Center for Endocrinology, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГК «Герофарм»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>GEROPHARM</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>06</day><month>09</month><year>2019</year></pub-date><volume>0</volume><issue>3</issue><fpage>47</fpage><lpage>55</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Майоров А.Ю., Авдеева О.И., Кокшарова Е.О., Беликова Т.М., Мишина Е.Е., Драй Р.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Майоров А.Ю., Авдеева О.И., Кокшарова Е.О., Беликова Т.М., Мишина Е.Е., Драй Р.В.</copyright-holder><copyright-holder xml:lang="en">Mayorov A., Avdeeva O., Koksharova E., Belikova T., Mishina E., Dray R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/102">https://www.pharmacokinetica.ru/jour/article/view/102</self-uri><abstract/><trans-abstract xml:lang="en"><p>Justification. On average, about 12 % of all global healthcare spending on diabetes. One of the first domestic human insulin preparations was Rinsulin® R, the biosimilar (bioanalog) of Humulin® Regular. The clinical research program for biosimilars of insulin preparations includes pharmacology studies: pharmacokinetics, pharmacodynamics and clinical safety research. Purpose. Evaluation of the biosimilarity of the Rinsulin® R (biosimilar) and Humulin® Regular (original) preparations in the conditions of hyperinsulinemic euglycemic clamp in healthy volunteers. Materials and methods. The study was conducted on healthy male volunteers aged 18 to 50 years. Study design is a double-blind, randomized, cross-sectional study of comparative pharmacokinetics and pharmacodynamics of drugs. The drugs were injected subcutaneously into the anterior abdominal wall at a dose of 0.3 IU / kg once. The duration of blood sampling to determine the pharmacokinetic parameters was 10 hours: the concentration of insulin in the blood was determined by enzyme-linked immunosorbent assay. Based on the level of glycemia, the glucose infusion rate was adjusted, the data of which were used to calculate the pharmacodynamic parameters. Results and discussion. It was found that the studied drugs are characterized by a high degree of similarity of pharmacokinetics and pharmacodynamics. 90 % confidence intervals for the ratios of the geometric mean values of the primary pharmacokinetics AUCins.0-t and Cins.max fully correspond to the permissible limits of 80-125 % and are, respectively, 88.61-111.52 and 85.411-109,51 %. 95 % confidence intervals for the ratios of the geometric mean values of the primary pharmacodynamics AUCGIR0-t and GIRmax fully correspond to the permissible limits of 80-125 % and are, respectively, 93.48-112.29 and 95.75-109.17 %. Of particular clinical significance are the synchronous onset of action of drugs, the time of onset of the maximum effect and duration of action. The frequency of adverse events was comparable in the drug groups. Conclusions. Rinsulin® R and Humulin® Regular are equivalent.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инсулин генно-инженерный человеческий</kwd><kwd>биосимиляр</kwd><kwd>фармакокинетика</kwd><kwd>фармакодинамика</kwd><kwd>гиперинсулинемический эугликемический клэмп</kwd><kwd>genetic engineering human insulin</kwd><kwd>biosimilar</kwd><kwd>pharmacokinetics</kwd><kwd>pharmacodynamics</kwd><kwd>hyperinsulinemic euglycemic clamp</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Diabetes Atlas. IDF, 2017.</mixed-citation><mixed-citation xml:lang="en">Diabetes Atlas. IDF, 2017.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральный регистр больных сахарным диабетом. [Federal'nyj registr bol'nyh saharnym diabetom. [Internet] (In Russ).] URL: http://diaregistry.ru (дата обращения 03.2019).</mixed-citation><mixed-citation xml:lang="en">Федеральный регистр больных сахарным диабетом. [Federal'nyj registr bol'nyh saharnym diabetom. [Internet] (In Russ).] URL: http://diaregistry.ru (дата обращения 03.2019).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British journal of clinical pharmacology. 1999;48(5):643–648.</mixed-citation><mixed-citation xml:lang="en">King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British journal of clinical pharmacology. 1999;48(5):643–648.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Демидов Н.А., Мишра О.А. Эффективность и безопасность использования Ринсулина Р и Ринсулина НПХ в условиях амбулаторной практики // РМЖ. – 2016. – № 12. – С. 782–785. [Demidov NA, Mishra OA. Effektivnost' i bezopasnost' ispol'zovaniya Rinsulina R i Rinsulina NPH v usloviyah ambulatornojpraktiki. RMJ. 2016;12:782–785. (In Russ).]</mixed-citation><mixed-citation xml:lang="en">Демидов Н.А., Мишра О.А. Эффективность и безопасность использования Ринсулина Р и Ринсулина НПХ в условиях амбулаторной практики // РМЖ. – 2016. – № 12. – С. 782–785. [Demidov NA, Mishra OA. Effektivnost' i bezopasnost' ispol'zovaniya Rinsulina R i Rinsulina NPH v usloviyah ambulatornojpraktiki. RMJ. 2016;12:782–785. (In Russ).]</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues (EMEA/CHMP/BMWP/32775/2005_Rev. 1).</mixed-citation><mixed-citation xml:lang="en">Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues (EMEA/CHMP/BMWP/32775/2005_Rev. 1).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on similar biological medicinal products (CHMP/437/04 Rev. 1).</mixed-citation><mixed-citation xml:lang="en">Guideline on similar biological medicinal products (CHMP/437/04 Rev. 1).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev. 1).</mixed-citation><mixed-citation xml:lang="en">Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev. 1).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins (EMEA/CHMP/ 89249/2004).</mixed-citation><mixed-citation xml:lang="en">Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins (EMEA/CHMP/ 89249/2004).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98).</mixed-citation><mixed-citation xml:lang="en">Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins (EMEA/CHMP/BMWP/14327/2006).</mixed-citation><mixed-citation xml:lang="en">Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins (EMEA/CHMP/BMWP/14327/2006).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Решение № 89 от 3 ноября 2016 года "Об утверждении правил проведения исследований биологических лекарственных средств Евразийского экономического союза», глава 15.7 «Доклиническая и клиническая разработка биоаналогичных (биоподобных) лекарственных препаратов, содержащих рекомбинантный инсулин и аналоги инсулина». [Decision № 89 of Nov 3 2016 "Ob utverzhdenii pravil provedeniya issledovaniy biologicheskikh lekarstvennykh sredstv Evraziyskogo ekonomicheskogo soyuza", glava 15.7 "Doklinicheskaya i klinicheskaya razrabotka bioanalogichnyh (biopodobnyh) lekarstvennyh preparatov, soderzhashchih rekombinantnyj insulin i analogi insulina". (In Russ).]</mixed-citation><mixed-citation xml:lang="en">Решение № 89 от 3 ноября 2016 года "Об утверждении правил проведения исследований биологических лекарственных средств Евразийского экономического союза», глава 15.7 «Доклиническая и клиническая разработка биоаналогичных (биоподобных) лекарственных препаратов, содержащих рекомбинантный инсулин и аналоги инсулина». [Decision № 89 of Nov 3 2016 "Ob utverzhdenii pravil provedeniya issledovaniy biologicheskikh lekarstvennykh sredstv Evraziyskogo ekonomicheskogo soyuza", glava 15.7 "Doklinicheskaya i klinicheskaya razrabotka bioanalogichnyh (biopodobnyh) lekarstvennyh preparatov, soderzhashchih rekombinantnyj insulin i analogi insulina". (In Russ).]</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Разработка биоаналогичных (биоподобных) лекарственных препаратов, содержащих в качестве фармацевтической субстванции генно-инженерный инсулин человека или аналоги инсулина человека // Руководство по экспертизе лекарственных средств. Том IV. – М.: Полиграф-плюс; 2014. [Razrabotka bioanalogichnykh (biopodobnykh) lekarstvennykh preparatov, soderzhashchikh v kachestve farmatsevticheskoy substvantsii genno-inzhenernyy insulin cheloveka ili analogi insulina cheloveka. In: Rukovodstvo po ekspertize lekarstvennykh sredstv. Vol. IV. Moscow: Poligraf-plyus; 2014. (In Russ).]</mixed-citation><mixed-citation xml:lang="en">Разработка биоаналогичных (биоподобных) лекарственных препаратов, содержащих в качестве фармацевтической субстванции генно-инженерный инсулин человека или аналоги инсулина человека // Руководство по экспертизе лекарственных средств. Том IV. – М.: Полиграф-плюс; 2014. [Razrabotka bioanalogichnykh (biopodobnykh) lekarstvennykh preparatov, soderzhashchikh v kachestve farmatsevticheskoy substvantsii genno-inzhenernyy insulin cheloveka ili analogi insulina cheloveka. In: Rukovodstvo po ekspertize lekarstvennykh sredstv. Vol. IV. Moscow: Poligraf-plyus; 2014. (In Russ).]</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Heinemann L, Anderson JH. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004 Oct;6(5):698–718. DOI: 10.1089/dia.2004.6.698</mixed-citation><mixed-citation xml:lang="en">Heinemann L, Anderson JH. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004 Oct;6(5):698–718. DOI: 10.1089/dia.2004.6.698</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Heise T, Zijlstra E, Nosek L, et al. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016 Oct;18(10):962–972. DOI: 10.1111/dom.12703</mixed-citation><mixed-citation xml:lang="en">Heise T, Zijlstra E, Nosek L, et al. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016 Oct;18(10):962–972. DOI: 10.1111/dom.12703</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Rabiee A, Magruder JT, Grant C, et al. Accuracy and reliability of the Nova StatStrip® glucose meter for real-time blood glucose determinations during glucose clamp studies. J Diabetes Sci Technol. 2010 Sep 1;4(5):1195–1201. DOI: 10.1177/193229681000400519</mixed-citation><mixed-citation xml:lang="en">Rabiee A, Magruder JT, Grant C, et al. Accuracy and reliability of the Nova StatStrip® glucose meter for real-time blood glucose determinations during glucose clamp studies. J Diabetes Sci Technol. 2010 Sep 1;4(5):1195–1201. DOI: 10.1177/193229681000400519</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lindquist KA, Chow K, West A, et al. The StatStrip glucose monitor is suitable for use during hyperinsulinemic euglycemic clamps in a pediatric population. Diabetes technology &amp; therapeutics. 2014;16(5):298–302.</mixed-citation><mixed-citation xml:lang="en">Lindquist KA, Chow K, West A, et al. The StatStrip glucose monitor is suitable for use during hyperinsulinemic euglycemic clamps in a pediatric population. Diabetes technology &amp; therapeutics. 2014;16(5):298–302.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21(11):1910–1914. DOI: 10.2337/diacare.21.11.1910</mixed-citation><mixed-citation xml:lang="en">Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21(11):1910–1914. DOI: 10.2337/diacare.21.11.1910</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
